Skip to main content

Advertisement

Table 1 Description of pilot samples and study cohorts

From: Neuronal methylome reveals CREB-associated neuro-axonal impairment in multiple sclerosis

  Pilot samples Cohort 1 Cohort 2 Cohort IF
Group Case Control Case Control Case Control Case Control
N individualsa 1 1 5 5 10 7 7 8
Sex ratio (F/M) 1:0 0:1 4:1 1:4 7:3 3:4 6:1 3:5
Age (mean ± SD) 42 92 45.4 ± 4.5 68.4 ± 21.6 60.3 ± 12.4 78.5 ± 7.9 63.6 ± 12.8 78.2 ± 5.1
PMI (mean ± SD) 11 13 17 ± 8.7 21 ± 7.4 17 ± 9.3 11 ± 11.4 15 ± 8.0 23 ± 3.7
N brain samples 4 1 7 5 10 7 7 8
Type lesion (N) AL (1)   AL (2)    
CAL (1)  
CL (1) CL (2) CL (2)  
NAWM (1) NAWM (3) NAWM (8) NAWM (7)  
Sample type Bulk tissue and neurons Neurons Neurons Meurons
Location GM, WM, mixed WM WM WM and GM
Modification DNA methylation DNA methylation DNA methylation Protein phosphorylation
Analysis Bulk BS
(mixed 5mC/5hmC)
Bulk BS
(mixed 5mC/5hmC)
BS and oxBS
(5mC, 5hmC)
IF: P-CREB
  1. aThree individuals (2 MS cases and 1 control) overlapped between cohort 1 and 2, although different brain samples were used, and, eight individuals (5 MS cases and 3 controls) were used for both DNA methylation (cohort 2) and immunofluorescence (cohort IF) analyses, among which 4 brain specimens were identical. N number, F/M female/male, PMI post-mortem interval, AL active lesion, CL chronic lesion, CAL chronic active lesion, NAWM normal-appearing white matter, GM grey matter, WM white matter, BS bisulfite, oxBS oxidative bisulfite, 5mC methylation, 5hmC hydroxymethylation, P-CREB phosphorylated CREB, SD standard deviation, IF immunofluorescence